尽管有内部人士抛售，波士顿科学公司仍以强劲的收入增长超出盈利预期，并上调了第三季度的展望。 Boston Scientific beat earnings expectations with strong revenue growth and raised its Q3 outlook, despite insider selling.

波士顿科学社(BSX)报告第二季度收入强劲,收入为7.5 EPS和5.06亿美元,比上一年增加22.8%。 Boston Scientific (BSX) reported strong second-quarter earnings, with $0.75 EPS and $5.06 billion in revenue, up 22.8% year-over-year. 该公司价值1 406亿美元,项目Q3 2025 EPS为0.70美元至0.72美元,具有协商一致的“Buy”评级。 The company, valued at $140.6 billion, projects Q3 2025 EPS of $0.70–$0.72 and has a consensus “Buy” rating. 波伦资本收购了2%的股份,理由是其MedSurg和心血管部门的增长. Polen Capital acquired a 2% stake, citing growth in its MedSurg and Cardiovascular segments. 尽管90天内内幕销售总额达1 797万美元,但股票比去年增长了9.43%,到2025年10月13日已接近94.95美元。 Despite insider selling totaling $17.97 million in 90 days, the stock rose 9.43% over the past year, closing at $94.95 on October 13, 2025.